Why Is Foghorn Therapeutics Stock Tumbling Today? - Foghorn Therapeutics (NASDAQ:FHTX)

Foghorn Therapeutics' stock plunged 31.2% to $2.01 after it and Eli Lilly ended their collaboration due to insufficient clinical efficacy in a Phase 1 trial. Analysts downgraded the stock and cut price targets, citing the loss of a key partnership and a 40% workforce reduction. The company's pipeline is now entirely preclinical, raising concerns about its future.

Analysts downgraded several companies: Foghorn Therapeutics (FHTX) to Neutral, First Busey (BUSE) to Neutral with a $30 target, AST SpaceMobile (ASTS) to Neutral with a $65 target, AtriCure (ATRC) to Hold with a $57 target, and Equity Bancshares (EQBK) to Neutral with a $52 target. ASTS closed at $57.04 on Thursday.

Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral, lowering its price target to $2.00. The move follows the discontinuation of FHD-909, a drug in collaboration with Eli Lilly, due to Phase 1 data. Foghorn is cutting 40% of its workforce and realigning operations. Other analysts have also lowered price targets, though some maintain positive ratings.

H.C. Wainwright cut Foghorn Therapeutics' (FHTX) price target to $5 from $13 after it halted the FHD-909 program due to lack of efficacy. FHTX stock is down 16.57% this week. The company reduced its workforce by 40% and expects cash runway into 2H 2029. Multiple analysts downgraded FHTX, with price targets now ranging from $2 to $5.

Guggenheim cut Foghorn Therapeutics' (FHTX) price target to $5.00 from $12.00, maintaining a Buy rating, after the company discontinued its lead drug program FHD-909. Foghorn and partner Eli Lilly halted the program due to insufficient efficacy in Phase 1 trials. The stock is down 16.6% over the past week, trading at $2.92. Analysts have mixed reactions, with some downgrading and others maintaining Buy ratings with adjusted targets.

TD Cowen downgraded Foghorn Therapeutics (FHTX) to Hold from Buy after it and Eli Lilly halted FHD-909's development. The stock fell to $2.92, down 33.89% YTD. Foghorn plans to cut 40% of its workforce and focus on preclinical programs, extending its cash runway. Analysts have mixed views on its valuation and future prospects.